Inhibition of de novo Palmitate Synthesis by Fatty Acid Synthase Induces Apoptosis in Tumor Cells by Remodeling Cell Membranes, Inhibiting Signaling Pathways, and Reprogramming Gene Expression

EBioMedicine

Volumn 2, Issue 8, 2015, Pages 808-824

  Ventura, Richard ^a   Mordec, Kasia ^a   Waszczuk, Joanna ^a   Wang, Zhaoti ^a   Lai, Julie ^a   Fridlib, Marina ^a   Buckley, Douglas ^a   Kemble, George ^a   Heuer, Timothy S ^a  

^a 3 V Biosciences ^*  (United States)

Author keywords

Beta catenin; Fatty acid synthase; Inhibitor; KRAS; Lipid raft; MYC

Indexed keywords

FATTY ACID SYNTHASE; PALMITIC ACID; ENZYME INHIBITOR; FASN PROTEIN, HUMAN; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; CELL GROWTH; CELL VIABILITY; CONTROLLED STUDY; ENZYME SYNTHESIS; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IC50; IMMUNOFLUORESCENCE; LIPIDOMICS; LIPOGENESIS; MASS SPECTROMETRY; NUCLEAR REPROGRAMMING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL MEMBRANE; GENE EXPRESSION REGULATION; METABOLISM; NEOPLASM; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL MEMBRANE; ENZYME INHIBITORS; FATTY ACID SYNTHASE, TYPE I; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; PALMITIC ACID; SIGNAL TRANSDUCTION;

EID: 84949818415     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2015.06.020     Document Type: Article

References (51)

1. Abulrob A., Giuseppin S., Andrade M.F., McDermid A., Moreno M., Stanimirovic D. Interactions of EGFR and caveolin-1 in human glioblastoma cells: evidence that tyrosine phosphorylation regulates EGFR association with caveolae. Oncogene 2004, 23:6967-6979.
2. Ahearn I.M., Haigis K., Bar-Sagi D., Philips M.R. Regulating the regulator: post-translational modification of RAS. Nat. Rev. Mol. Cell Biol. 2012, 13:39-51.
3. Benjamin D.I., Li D.S., Lowe W., Heuer T., Kemble G., Nomura D.K. Diacylglycerol metabolism and signaling is a driving force underlying FASN inhibitor sensitivity in cancer cells. ACS Chem. Biol. 2015, (in press) (Apr 17, Epub ahead of print).
4. Chirala S.S., Chang H., Matzuk M., Abu-Elheiga L., Mao J., Mahon K., Finegold M., Wakil S.J. Fatty acid synthesis is essential in embryonic development: fatty acid synthase null mutants and most of the heterozygotes die in utero. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:6358-6363.
5. Choi W.I., Jeon B.N., Park H., Yoo J.Y., Kim Y.S., Koh D.I., Kim M.H., Kim Y.R., Lee C.E., Kim K.S., Osborne T.F., Hur M.W. Proto-oncogene FBI-1 (Pokemon) and SREBP-1 synergistically activate transcription of fatty-acid synthase gene (FASN). J. Biol. Chem. 2008, 283:29341-29354.
6. Chuang H.Y., Chang Y.F., Hwang J.J. Antitumor effect of orlistat, a fatty acid synthase inhibitor, is via activation of caspase-3 on human colorectal carcinoma-bearing animal. Biomed. Pharmacother. 2011, 65:286-292.
7. Clevers H., Nusse R. Wnt/beta-catenin signaling and disease. Cell 2012, 149:1192-1205.
8. Donahue T.R., Tran L.M., Hill R., Li Y., Kovochich A., Calvopina J.H., Patel S.G., Wu N., Hindoyan A., Farrell J.J., Li X., Dawson D.W., Wu H. Integrative survival-based molecular profiling of human pancreatic cancer. Clin. Cancer Res. 2012, 18:1352-1363.
9. Eisenberg S., Beckett A.J., Prior I.A., Dekker F.J., Hedberg C., Waldmann H., Ehrlich M., Henis Y.I. Raft protein clustering alters N-Ras membrane interactions and activation pattern. Mol. Cell. Biol. 2011, 31:3938-3952.
10. Eisenberg S., Laude A.J., Beckett A.J., Mageean C.J., Aran V., Hernandez-Valladares M., Henis Y.I., Prior I.A. The role of palmitoylation in regulating Ras localization and function. Biochem. Soc. Trans. 2013, 41:79-83.
11. Fiorentino M., Zadra G., Palescandolo E., Fedele G., Bailey D., Fiore C., Nguyen P.L., Migita T., Zamponi R., Di Vizio D., Priolo C., Sharma C., Xie W., Hemler M.E., Mucci L., Giovannucci E., Finn S., Loda M. Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer. Lab. Investig. 2008, 88:1340-1348.
12. Flavin R., Peluso S., Nguyen P.L., Loda M. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol. 2010, 6:551-562.
13. Grunt T.W., Wagner R., Grusch M., Berger W., Singer C.F., Marian B., Zielinski C.C., Lupu R. Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells. Biochem. Biophys. Res. Commun. 2009, 385:454-459.
14. Hollander M.C., Blumenthal G.M., Dennis P.A. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat. Rev. Cancer 2011, 11:289-301.
15. Janes P.W., Ley S.C., Magee A.I. Aggregation of lipid rafts accompanies signaling via the T cell antigen receptor. J Cell Biol 1999, 147:447-461.
16. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Kamiyama H., Jimeno A., Hong S.M., Fu B., Lin M.T., Calhoun E.S., Kamiyama M., Walter K., Nikolskaya T., Nikolsky Y., Hartigan J., Smith D.R., Hidalgo M., Leach S.D., Klein A.P., Jaffee E.M., Goggins M., Maitra A., Iacobuzio-Donahue C., Eshleman J.R., Kern S.E., Hruban R.H., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., Kinzler K.W. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806.
17. Kant S., Kumar A., Singh S.M. Fatty acid synthase inhibitor orlistat induces apoptosis in T cell lymphoma: role of cell survival regulatory molecules. Biochim. Biophys. Acta 2012, 1820:1764-1773.
18. Kridel S.J. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res. 2004, 64:2070-2075.
19. Lasserre R., Guo X.J., Conchonaud F., Hamon Y., Hawchar O., Bernard A.M., Soudja S.M., Lenne P.F., Rigneault H., Olive D., Bismuth G., Nunes J.A., Payrastre B., Marguet D., He H.T. Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activation. Nat. Chem. Biol. 2008, 4:538-547.
20. Lingwood D., Simons K. Lipid rafts as a membrane-organizing principle. Science 2010, 327:46-50.
21. Liu H., Liu J.Y., Wu X., Zhang J.T. Biochemistry, molecular biology, and pharmacology of fatty acid synthase, an emerging therapeutic target and diagnosis/prognosis marker. Int. J. Biochem. Mol. Biol. 2010, 1:69-89.
22. Lupu R., Menendez J.A. Targeting fatty acid synthase in breast and endometrial cancer: an alternative to selective estrogen receptor modulators?. Endocrinology 2006, 147:4056-4066.
23. Maier T., Jenni S., Ban N. Architecture of mammalian fatty acid synthase at 4.5A resolution. Science 2006, 311:1258-1262.
24. Menendez J.A., Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat. Rev. Cancer 2007, 7:763-777.
25. Nguyen P.L., Ma J., Chavarro J.E., Freedman M.L., Lis R., Fedele G., Fiore C., Qiu W., Fiorentino M., Finn S., Penney K.L., Eisenstein A., Schumacher F.R., Mucci L.A., Stampfer M.J., Giovannucci E., Loda M. Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival. J. Clin. Oncol. 2010, 28:3958-3964.
26. Notarnicola M., Tutino V., Calvani M., Lorusso D., Guerra V., Caruso M.G. Serum levels of fatty acid synthase in colorectal cancer patients are associated with tumor stage. J. Gastrointest. Cancer 2012, 43:508-511.
27. Oslob J.D., Johnson R.J., Cai H., Feng S.Q., Hu L., Kosaka Y., Lai J., Sivaraja M., Tep S., Yang H., Zaharia C.A., Evanchik M.J., McDowell R.S. Imidazopyridine-based fatty acid synthase inhibitors that show anti-HCV activity and in vivo target modulation. ACS Med. Chem. Lett. 2013, 4:113-117.
28. Oslob J.D.M., Robert S., Johnson Russell, Yang Hanbiao, Evanchik Marc, Zaharia Cristiana A., Cai Haiying, Hu Lily W. (Acylaryl)imidazoles as modulators of lipid synthesis and their preparation WO 2014008197 A1 20140109 2014.
29. Puig T., Vazquez-Martin A., Relat J., Petriz J., Menendez J.A., Porta R., Casals G., Marrero P.F., Haro D., Brunet J., Colomer R. Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75. Breast Cancer Res. Treat. 2008, 109:471-479.
30. Puig T., Turrado C., Benhamu B., Aguilar H., Relat J., Ortega-Gutierrez S., Casals G., Marrero P.F., Urruticoechea A., Haro D., Lopez-Rodriguez M.L., Colomer R. Novel inhibitors of fatty acid synthase with anticancer activity. Clin. Cancer Res. 2009, 15:7608-7615.
31. Puig T., Aguilar H., Cufi S., Oliveras G., Turrado C., Ortega-Gutierrez S., Benhamu B., Lopez-Rodriguez M.L., Urruticoechea A., Colomer R. A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines. Breast Cancer Res. 2011, 13:R131.
32. Reis-Sobreiro M., Roue G., Moros A., Gajate C., De La Iglesia-Vicente J., Colomer D., Mollinedo F. Lipid raft-mediated Akt signaling as a therapeutic target in mantle cell lymphoma. Blood Cancer J. 2013, 3:e118.
33. Sebastiani V., Botti C., Di Tondo U., Visca P., Pizzuti L., Santeusanio G., Alo P.L. Tissue microarray analysis of FAS, Bcl-2, Bcl-x, ER, PgR, Hsp60, p53 and Her2-neu in breast carcinoma. Anticancer Res. 2006, 26:2983-2987.
34. Shackelford D.B., Shaw R.J. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat. Rev. Cancer 2009, 9:563-575.
35. Shah U.S., Dhir R., Gollin S.M., Chandran U.R., Lewis D., Acquafondata M., Pflug B.R. Fatty acid synthase gene overexpression and copy number gain in prostate adenocarcinoma. Hum. Pathol. 2006, 37:401-409.
36. Shearn C.T., Mercer K.E., Orlicky D.J., Hennings L., Smathers-McCullough R.L., Stiles B.L., Ronis M.J., Petersen D.R. Short term feeding of a high fat diet exerts an additive effect on hepatocellular damage and steatosis in liver-specific PTEN knockout mice. PLoS One 2014, 9:e96553.
37. Simons K., Sampaio J.L. Membrane organization and lipid rafts. Cold Spring Harb. Perspect. Biol. 2011, 3:a004697.
38. Son J., Lyssiotis C.A., Ying H., Wang X., Hua S., Ligorio M., Perera R.M., Ferrone C.R., Mullarky E., Shyh-Chang N., Kang Y., Fleming J.B., Bardeesy N., Asara J.M., Haigis M.C., Depinho R.A., Cantley L.C., Kimmelman A.C. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 2013, 496:101-105.
39. Song S.P., Hennig A., Schubert K., Markwart R., Schmidt P., Prior I.A., Bohmer F.D., Rubio I. Ras palmitoylation is necessary for N-Ras activation and signal propagation in growth factor signalling. Biochem. J. 2013, 454:323-332.
40. Staubach S., Hanisch F.G. Lipid rafts: signaling and sorting platforms of cells and their roles in cancer. Expert Rev. Proteomics 2011, 8:263-277.
41. Tao B.B., He H., Shi X.H., Wang C.L., Li W.Q., Li B., Dong Y., Hu G.H., Hou L.J., Luo C., Chen J.X., Chen H.R., Yu Y.H., Sun Q.F., Lu Y.C. Up-regulation of USP2a and FASN in gliomas correlates strongly with glioma grade. J. Clin. Neurosci. 2013, 20:717-720.
42. Tomek K., Wagner R., Varga F., Singer C.F., Karlic H., Grunt T.W. Blockade of fatty acid synthase induces ubiquitination and degradation of phosphoinositide-3-kinase signaling proteins in ovarian cancer. Mol. Cancer Res. 2011, 9:1767-1779.
43. Ueda S.M., Yap K.L., Davidson B., Tian Y., Murthy V., Wang T.L., Visvanathan K., Kuhajda F.P., Bristow R.E., Zhang H., Shih Ie M. Expression of fatty acid synthase depends on NAC1 and is associated with recurrent ovarian serous carcinomas. J. Oncol. 2010, 2010:285191.
44. Van De Sande T., Roskams T., Lerut E., Joniau S., Van Poppel H., Verhoeven G., Swinnen J.V. High-level expression of fatty acid synthase in human prostate cancer tissues is linked to activation and nuclear localization of Akt/PKB. J. Pathol. 2005, 206:214-219.
45. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2002, 2:489-501.
46. Ward P.S., Thompson C.B. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 2012, 21:297-308.
47. Witkiewicz A.K., Nguyen K.H., Dasgupta A., Kennedy E.P., Yeo C.J., Lisanti M.P., Brody J.R. Co-expression of fatty acid synthase and caveolin-1 in pancreatic ductal adenocarcinoma: implications for tumor progression and clinical outcome. Cell Cycle 2008, 7:3021-3025.
48. Yachida S., Jones S., Bozic I., Antal T., Leary R., Fu B., Kamiyama M., Hruban R.H., Eshleman J.R., Nowak M.A., Velculescu V.E., Kinzler K.W., Vogelstein B., Iacobuzio-Donahue C.A. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010, 467:1114-1117.
49. Ying H., Kimmelman A.C., Lyssiotis C.A., Hua S., Chu G.C., Fletcher-Sananikone E., Locasale J.W., Son J., Zhang H., Coloff J.L., Yan H., Wang W., Chen S., Viale A., Zheng H., Paik J.H., Lim C., Guimaraes A.R., Martin E.S., Chang J., Hezel A.F., Perry S.R., Hu J., Gan B., Xiao Y., Asara J.M., Weissleder R., Wang Y.A., Chin L., Cantley L.C., Depinho R.A. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 2012, 149:656-670.
50. Zaytseva Y.Y., Rychahou P.G., Gulhati P., Elliott V.A., Mustain W.C., O'Connor K., Morris A.J., Sunkara M., Weiss H.L., Lee E.Y., Evers B.M. Inhibition of fatty acid synthase attenuates CD44-associated signaling and reduces metastasis in colorectal cancer. Cancer Res. 2012, 72:1504-1517.
51. Zhu G., Wang Y., Huang B., Liang J., Ding Y., Xu A., Wu W. A Rac1/PAK1 cascade controls beta-catenin activation in colon cancer cells. Oncogene 2012, 31:1001-1012.